Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ATORVASTATIN Cause Post procedural complication? 21 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 21 reports of Post procedural complication have been filed in association with ATORVASTATIN (Atorvastatin calcium). This represents 0.0% of all adverse event reports for ATORVASTATIN.

21
Reports of Post procedural complication with ATORVASTATIN
0.0%
of all ATORVASTATIN reports
1
Deaths
7
Hospitalizations

How Dangerous Is Post procedural complication From ATORVASTATIN?

Of the 21 reports, 1 (4.8%) resulted in death, 7 (33.3%) required hospitalization, and 2 (9.5%) were considered life-threatening.

Is Post procedural complication Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ATORVASTATIN. However, 21 reports have been filed with the FAERS database.

What Other Side Effects Does ATORVASTATIN Cause?

Type 2 diabetes mellitus (7,556) Myalgia (7,155) Drug hypersensitivity (3,929) Drug ineffective (3,865) Fatigue (3,439) Arthralgia (3,338) Rhabdomyolysis (3,286) Dyspnoea (3,137) Nausea (2,888) Asthenia (2,791)

What Other Drugs Cause Post procedural complication?

ADALIMUMAB (2,494) ETANERCEPT (318) CALCIUM\DEXTROSE\MAGNESIUM\SODIUM\SODIUM (244) UPADACITINIB (241) RISANKIZUMAB-RZAA (232) INFLIXIMAB (217) METHOTREXATE (188) TREPROSTINIL (174) HUMAN IMMUNOGLOBULIN G (159) PREDNISONE (157)

Which ATORVASTATIN Alternatives Have Lower Post procedural complication Risk?

ATORVASTATIN vs ATORVASTATIN\EZETIMIBE ATORVASTATIN vs ATOSIBAN ATORVASTATIN vs ATOVAQUONE ATORVASTATIN vs ATOVAQUONE\PROGUANIL ATORVASTATIN vs ATRACURIUM

Related Pages

ATORVASTATIN Full Profile All Post procedural complication Reports All Drugs Causing Post procedural complication ATORVASTATIN Demographics